Programme 10 February
The programme is subject to changes.
09:15–09:45 | Opening of Norway Life Science 2026
- Ragnhild Hennum,?Rector, University of Oslo
- Eirik Lae Solberg, Governing Mayor of?Oslo
- Sigrun Aasland, Minister of Research and Higher Education
Hosts
- Carl Henrik G?rbitz, Director, UiO:Life Science, University of Oslo
- Christine Wergeland S?rbye?CEO, Oslo Science City
09:45–10:10 | Global perspectives on how to develop a life science industry in Norway
- Christian Rommel, Global Head of R&D Bayer
- Paul Evans, Head of Global R&D, GE Healthcare
- Idar Kreutzer, NHO (moderator)
10:10–10:45 | Keynote session: Norwegian life science strong points
Radiopharmacy?
- Mona Elisabeth Rootwelt-Revheim, Group leader, The Intervention Centre, Oslo University Hospital & Professor II, University of Oslo
Neuroscience and AI
- Ira Haraldsen, Group leader Cognitive Health Research Group, Oslo University Hospital
Ocean health?
- Kristine Hartmann, CEO Salmon Living Lab ?
10:45–11:15 Break
11:15–12:15 | Parallel sessions: Norwegian life science strong points
Radiopharmacy
Radioligand therapy and theranostics – a new era in cancer treatment.
Welcome by moderator Thor Audun Saga, CEO, Norwegian Medical Cyclotron Center
What’s in for the patients??
- ?se Bratland, Head of section, Oslo University Hospital
Norwegian strongholds in academic research in Nuclear medicine?
- Sunniva Siem, Professor, University of Oslo
Norwegian start-up scene and industry investments in radioligand therapy and theranostics
- Evy Stavik Global Head of CMC Development, R&D, GE HealthCare
- Thomas Birger Eden-Jensen, Manufacturing and Supply Chain Leader, Bayer
- Jasper Kurth, CEO, Thor Medical
- Ingrid Teigland Akay, Managing Partner, Hadean Venture?
Incentives to support competitiveness in Norwegian strongholds such as radioligand therapy and diagnostics?
- Birgitte Gangmark Villmo, Investment Director, Investinor
- Karin ?yaas, Special Advisor, Siva
- Tone Varslot Stave, Head of Health, Innovation Norway
- Ole Johan Borge, Director of Health Research and Innovation, Research Council of Norway?
?
Event organizer: Oslo Cancer Cluster, LMI and Oslo Science City
Neuroscience and AI?
How is artificial intelligence transforming neuroscience – from research and diagnostics to treatment and clinical decision support.
Artificial intelligence as a tool to predict antidote efficacy in fentanyl overdose models
- Nora Digranes, Researcher, Norwegian University of Life Sciences
The VIKING project – the development of a national health data infrastructure for neurological AI
- Kristian Bernhard Nilsen, Professor, Head of Section, Oslo University Hospital
From Research to Clinic: Multimodal AI for Alzheimer’s Care
- Anna C. Czerwinska, General Manager, precision-health.ai
Supporting treatment decisions for patients with Alzheimer's disease with explainable artificial intelligence
- Esten H. Leonardsen, CSO, Baba Vision
Moderator: Ronny Nordvik, Market Access & External Affairs Manager, AbbVie
Event organizer: Oslo University Hospital, Norway Health Tech and The Life Science Cluster
Ocean health
Sustainable Aquaculture and Healthy Oceans in Norway.
The invisible majority in ocean health
- Knut Rudi, Professor, NMBU
Ocean health: The need for marine science
- Ketil Hylland, Professor, UiO & Researcher Institute of Marine Research
Mortality in farmed Atlantic salmon, can we reach the goal of 5%?
- Marit Stormoen, Associate professor, NMBU
Biotechnology in aquaculture: Insights from the aquatic animal health industry
- Marius Karlsen, Senior Technical Manager Outcomes Research, Pharmaq part of Zoetis
Moderator: Bj?rn Jamtveit, Pro-Rector & Professor, UiO
Event organizer: SINTEF, The Life Science Cluster, Norwegian University of Life Sciences (NMBU) and University of Oslo (UiO).
12:15–13:15 Lunch
13:15–14:15 | The innovation game: How to create effective frameworks for transforming knowledge into fundable ventures
Part 1 The international picture
- Donald Ingber, Founding Director, Wyss Institute Harvard
- Jonathan Gertler, Managing Partner & CEO, Back Bay Life Science Advisors
- Andrew W. Lo, Charles E. and Susan T. Harris Professor, MIT Sloan School of Management (attending digitally)
Part 2 Norway and the Nordics
- Johanna Roostalu, Director Human Health, Venture Creation, BioInnovation Institute Fonden
- Erik Wold, Investment Director Investinor
- Tone Varslot Stave, Head of Health, Innovation Norway
- Karin Hultman, Senior Scientific Lead Innovation, Novo Nordisk Foundation?
Moderator: Benedicte Bakke, Portfolio Manager, DNB Asset Management
14:15–14:30 | The European Life Science Strategy: How, what and why?
- Peder S?gaard-Pedersen, Director Danish Industry Life Science
14:30–15:00 Break
15:00–15:50 | Life science competitiveness - Nordic and global perspectives
Introduction by chair Idar Kreutzer, NHO
- Christian Rommel, Executive Vice President, Global Head of R&D Bayer
- Jeppe Theisen, Vice President and Head of Business Area West, Novo Nordisk
- Ehab Youssef, Head of Europe Area North Roche
Rav Seeruthun, VP, Head of Medical Affairs, Europe, GSK
Paul Evans, Head of Global R&D, GE Healthcare
15:50–16:25 | Fireside Chat: Actions required to develop a competitive life science industry in Norway and increase national value creation
This session will be held in Norwegian, with translation to English available for non-Norwegian speakers.
?
- Erlend Svardal B?e, Parliament member Conservative Party
- Truls Vasvik, Parliament member Labour Party
- Ole Erik Almlid, CEO NHO
- Jens Petter Berg, Vice-Rector, University of Oslo
- Cathrine Thomassen, General Manager GE HealthCare
Chair: Marius Lorentzen, Finansavisen (The Norwegian Financial Daily)
16:25 | Closing Remarks
17:30–19:00 Reception in Domus Bibliotheca
The doors open at 16:45. The event starts at 17:30